Clinical Study

Acquired Melanonychia in Chilean Patients with Essential Thrombocythemia Treated with Hydroxyurea: A Report of 7 Clinical Cases and Review of the Literature

Nigel P. Murray,1,2 Pablo Tapia,3 Jose Porcell,3 Maximiliano Echavarria,4 and Hernán Suazo5

1 Hematology Department, Hospital de Carabineros, Simon Bolivar 2200, Nunoa, 7770199 Santiago, Chile
2 Faculty of Medicine, University Mayor, Renato Sanchez 4369, Las Condes, 27550224 Santiago, Chile
3 Division of Medicine, Hospital de Carabineros, Simon Bolivar 2200, Nunoa, 7770199 Santiago, Chile
4 Faculty of Dentistry, University de Desarrollo, Avenida Las Condes 12 438, Lo Barnechea, 27470325 Santiago, Chile
5 Pharmacy Department, Hospital de Carabineros, Simon Bolivar 2200, Nunoa, 7770199 Santiago, Chile

Correspondence should be addressed to Nigel P. Murray; nigelpetermurray@gmail.com

Received 16 December 2012; Accepted 13 January 2013

Academic Editors: E. Pasmatzi, Y. Tuzun, and J. F. Val Bernal

Copyright © 2013 Nigel P. Murray et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Longitudinal melanonychia has been associated with a range of drugs, especially chemotherapeutic agents. We report 7 cases of melanonychia associated with the use of hydroxyurea for essential thrombocythemia. Of a patient population of 27, 7 (26%) developed melanonychia over a period of 2–7 years, and was not dose dependent. The high incidence of melanonychia in Chilean patients may be in part due to their Hispanic descent or to the high levels of UV radiation found in Santiago.

1. Introduction

We present 7 cases, five men and two women, all with a diagnosis of essential thrombocythemia, who presented with longitudinal dark pigmentation of the nails after a period of 3 to 5 years of treatment with hydroxyurea. Acquired longitudinal melanonychia is characterized by the presence of longitudinal brown or black lines in the nail plate as a result of increased melanin deposits. They originate in the nail matrix and are the result of an increased production of melanin by matrix melanocytes or of an increased number of melanocytes in the nail matrix.

2. Patients

Of 27 patients currently being followed up for essential thrombocythemia and being treated with hydroxyurea, 7 (26%) patients have developed melanonychia.

The clinical details of the 7 patients are shown in Table 1, with a mean age of 71.7 ± 9.8 years, and all the patients were treated with hydroxyurea for essential thrombocythemia for a median time of 5 years (range 2–7 years) and a median dose of 1,500 gm/day (range 500–2500 mg/day).

All patients did not have significant comorbidities and the use of other drugs was limited to aspirin 100 mg and in four patients the use of allopurinol 100 mg/day.

Nail examination (Figures 1(a) and 1(b)) showed a dark brown pigmentation distributed in well-defined longitudinal lines of varying width, and the nail was smooth and shiny. The lesions themselves were asymptomatic and Hutchinson’s sign was negative. With time, the lines occupied the full length of the nail. In two patients, there was a generalized hyperpigmentation of the skin. The number of nails affected was variable as was between nails of the hands and feet. There was no relation between the duration of hydroxyurea therapy or the dose used to control the essential thrombocythemia.

3. Controls

(a) Seven patients (6 men and 1 woman) with polycythemia rubra vera and treated with venesection for
### Table 1: Clinical features of nail pigmentation.

| Age | Sex | Mean dose/day | Time using hydroxyurea | Number of nails affected hands (feet) | Skin hyperpigmentation |
|-----|-----|--------------|------------------------|---------------------------------------|------------------------|
| 78  | M   | 1500 mg      | 2 years                | 3 (0)                                 | No                     |
| 84  | M   | 2500 mg      | 5 years                | 10 (10)                               | Yes                    |
| 63  | M   | 500 mg       | 6 years                | 2 (0)                                 | No                     |
| 59  | M   | 1000 mg      | 3 years                | 5 (2)                                 | No                     |
| 81  | M   | 500 mg       | 4 years                | 10 (10)                               | No                     |
| 64  | F   | 1500 mg      | 5 years                | 8 (4)                                 | No                     |
| 73  | F   | 2000 mg      | 7 years                | 6 (10)                                 | Yes                    |

Figure 1: (a) Close of longitudinal melanonychia. (b) Melanonychia of the thumb nail.

A median of 5 years were evaluated for melanonychia, and none of the 7 patients showed this condition.

(b) Fifty patients with atrial fibrillation attending an outpatient oral anticoagulant Clinic were also evaluated to assess the frequency of melanonychia in a general Chilean population, and 3 (6%) of these patients were identified as having this nail condition. The melanonychia involved 3 to 4 nails and was found in the hands but not in the feet.

### 4. Discussion

A healthy adult has approximately 200 melanocytes per mm² in the nail matrix, of which the majority remain dormant [1]. When these melanocytes are activated, melanosomes filled with melanin are transferred to differentiating matrix cells, which migrate distally as they become nail plate onychocytes [1]. This results in a visible band of pigmentation in the nail plate. The prevalence of affected individuals increases with age [2, 3], and there is a physiological or a racial component, being more common in African Americans or in those of Hispanic origin [4, 5]. The prevalence of melanonychia in the general population has been estimated to be 1%, increasing to 12% in hospitalized patients [6].

The largest reported series of melanonychia in patients with essential thrombocytopenia and associated with hydroxyurea was of 9 cases [7], there was no association with the dose or duration of treatment, and equally could affect the nails of both the hands and feet and could be associated or not with other dermatological changes such as skin hyperpigmentation. The same characteristics were observed in our series of 7 patients. Differing from our general outpatient population, in patients treated with hydroxyurea, the melanonychia occurred in both hands and feet, although more nails seemed to be affected in the hands.

Hydroxyurea is a cytostatic agent used in the treatment of myeloproliferation, inhibiting cellular DNA synthesis and promoting cell death in the S phase of the cell cycle [6]. It appears that hydroxyurea causes melanonychia by melanocytic activation. This is a process where there is increased melanin pigmentation of the nail matrix epithelium and nail plate without an increase in the number of melanocytes [8]. Although decreasing the dose or discontinuing the use of hydroxyurea could eliminate with time the melanonychia [8], the chronic nature of the underlying myeloproliferation and the few alternative treatments make a therapeutic change difficult. This adverse event is not considered sufficient to stop hydroxyurea treatment in patients with essential thrombocytopenia, according to a unified definition of clinical resistance or intolerance to hydroxyurea; however, it may precede the appearance of more serious mucocutaneous side effects such as skin ulceration or the development of skin carcinoma [9].
It has been postulated that one cause is photosensitivity, and in Santiago, Chile, the levels of UV radiation are high during most of the year, and this may be a contributing factor for the relatively high incidence of melanocytic in the patients taking hydroxycarbamide, apart from the racial influence of being of a Hispanic origin. The high UV radiation levels may also explain why the melanonychia was more common in the hands than in the feet and was only found in the hands of the control patients, reflecting total UV radiation exposure.

In the reported cases, it has been estimated that the risk of developing melanonychia in patients receiving treatment with hydroxycarbamide is 4%, more commonly in women and after a long period of treatment [10].

Longitudinal melanonychia of a single nail unit in an adult is concerning, and a biopsy of the nail unit can evaluate the possibility of melanoma, which cannot be differentiated from benign causes of longitudinal melanonychia solely based on clinical examination [11]. When nearly all the nails are affected in patients taking hydroxycarbamide, the diagnosis is consistent with melanonychia; however, it may be necessary for a biopsy in order to exclude acral lentiginous melanoma.

Conflict of Interests
The authors declare that they have no conflict of interests.

Acknowledgment
The authors would like to thank Mrs. Ana Maria Palazuelos for her help in writing this paper.

References
[1] J. Jefferson and P. Rich, “Melanonychia,” Dermatology Research and Practice, vol. 2012, Article ID 952186, 8 pages, 2012.
[2] E. Duhard, C. Clavet, N. Mariotte, J. Tichet, and L. Vaillant, “Prevalence of longitudinal melanonychia in white subjects,” Annales de Dermatologie et de Venereologie, vol. 122, no. 9, pp. 586–590, 1995.
[3] A. K. C. Leung, W. L. M. Robson, E. K. H. Liu et al., “Melanonychia striata in Chinese children and adults,” International Journal of Dermatology, vol. 46, no. 9, pp. 920–922, 2007.
[4] R. Baran and P. Kechijian, “Longitudinal melanonychia striata: diagnosis and management,” Journal of the American Academy of Dermatology, vol. 21, no. 6, pp. 1165–1175, 1989.
[5] J. Dominguez-Cherit, R. Roldan-Marin, P. Pichardo-Velazquez et al., “Melanonychia, melanocytic hyperplasia, and nail melanoma in a Hispanic population,” Journal of the American Academy of Dermatology, vol. 59, no. 5, pp. 785–791, 2008.
[6] R. Clerico, P. Corsetti, M. Ambriﬁ et al., “Longitudinal melanonychia in a patient with Essentia Thrombocytosis under treatment with hydroxyurea,” Acta Dermatovenerologica Croatica, vol. 20, pp. 272–283, 2012.
[7] N. Aste, G. Fumo, F. Contu, N. Aste, and P. Biggio, “Nail pigmentation caused by hydroxyurea: report of 9 cases,” Journal of the American Academy of Dermatology, vol. 47, no. 1, pp. 146–147, 2002.
[8] P. R. Kelsey, “Multiple longitudinal pigmented nail bands during hydroxyurea therapy,” Clinical and Laboratory Haematology, vol. 14, no. 4, pp. 337–338, 1992.
[9] A. Wiechert, G. Reinhard, T. Tüting, M. Uerlich, T. Bieber, and J. Wenzel, “Multiple skin cancers in a patient treated with hydroxyurea,” Hautarzt, vol. 60, no. 8, pp. 651–654, 2009.
[10] S. Neynaber, H. Wolff, G. Plewig, and R. Wienecke, “Longitudinal melanonychia induced by hydroxyurea therapy,” Journal der Deutschen Dermatologischen Gesellschaft, vol. 2, no. 7, pp. 588–591, 2004.
[11] K. E. Thai, R. Young, and R. D Sinclair, “Continuing medical education review: nail apparatus melanoma,” Australasian Journal of Dermatology, vol. 42, no. 2, pp. 71–81, 2001.